Objective:

To assess the real-world effectiveness and safety of upadacitinib in patients with atopic dermatitis (AD) involving anatomically sensitive areas, also referred to as 'special areas'.

Approach:

Key Findings:

• Upadacitinib provided rapid and sustained improvement in global disease severity and local involvement in sensitive areas, particularly in patients with mixed inflammatory pathways.
• Clinically meaningful responses were observed in patients with prior biologic exposure and overlap eczema–psoriasis phenotypes.
• Broad JAK1 inhibition may be particularly effective in sensitive areas characterized by mixed inflammatory pathways.

Interpretation:

The findings support the use of upadacitinib as an effective therapeutic option for patients with AD affecting special or sensitive sites, significantly improving quality of life.

Limitations:

• The study's retrospective design may introduce biases.
• Real-world data may not fully replicate controlled clinical trial conditions.
• The potential impact of missing data on the study's conclusions should be considered.

Conclusion:

Upadacitinib demonstrates efficacy in treating atopic dermatitis in sensitive regions, suggesting it is a valuable option for patients facing therapeutic challenges in these areas.

Source

Based on findings from:

Efficacy of Upadacitinib in Treating Atopic Dermatitis in Sensitive Regions: Outcomes from a Multicenter Real-World Study on Hand, Head/Neck, and Genital Involvement

Francisco Javier Melgosa Ramos, Santiago Guillén-Climent, Raquel Cavestany Rodriguez, Javier Sabater-Abad, Antonio Martorell, Fátima Tous Romero. Dermatology And Therapy, 2026.

https://link.springer.com/article/10.1007/s13555-026-01690-5

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.